Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. Sullivan RJ, et al. Among authors: pavlick ac. J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6. J Immunother Cancer. 2018. PMID: 29848375 Free PMC article.
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group. Bedikian AY, et al. Among authors: pavlick ac. J Clin Oncol. 2006 Oct 10;24(29):4738-45. doi: 10.1200/JCO.2006.06.0483. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966688 Clinical Trial.
Novel therapeutics for melanoma.
Seetharamu N, Ott PA, Pavlick AC. Seetharamu N, et al. Among authors: pavlick ac. Expert Rev Anticancer Ther. 2009 Jun;9(6):839-49. doi: 10.1586/era.09.40. Expert Rev Anticancer Ther. 2009. PMID: 19496721 Review.
KIT as a therapeutic target in metastatic melanoma.
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. Carvajal RD, et al. Among authors: pavlick ac. JAMA. 2011 Jun 8;305(22):2327-34. doi: 10.1001/jama.2011.746. JAMA. 2011. PMID: 21642685 Free PMC article. Clinical Trial.
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, Mohr P, Ottensmeier C, Chao D, Zhong B, de Boer CJ, Uhlar C, Marshall D, Gore ME, Lang Z, Hait W, Ho P; CNTO 95 Investigators. O'Day S, et al. Br J Cancer. 2011 Jul 26;105(3):346-52. doi: 10.1038/bjc.2011.183. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750555 Free PMC article. Clinical Trial.
178 results